Deterioration of kidney function by high doses of co-trimoxazole in man. 1987

T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden

High doses of co-trimoxazole in a patient with Pneumocystis carinii and impaired kidney function (creatinine clearance 10 ml/min) resulted in a declining renal clearance of the drug but did not affect the average creatinine clearance. The renal clearance of sulfamethoxazole and its metabolites 5-hydroxy-, N4-acetyl-, N4-acetyl-5-hydroxysulfamethoxazole decreased 80%, while the renal clearance of trimethoprim decreased 60%. The renal clearance of all compounds was evidently dependent on urine flow. The observed phenomena may be explained by the assumption that crystalluria occurred, obstructing kidney tubules. The crystalluria effect can be reversed by cessation of the drug or by lowering its dosage.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011020 Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis. P carinii Pneumonia,P. carinii Pneumonia,P. jirovecii Pneumonia,PCP Pneumonia,Pneumocystis Pneumonia,Pneumocystosis,Pneumonia, Interstitial Plasma Cell,PCP Infection,Pneumocystis carinii Pneumonia,Pneumocystis jirovecii Pneumonia,Pneumonia, Pneumocystis carinii,Infection, PCP,P carinii Pneumonias,P. carinii Pneumonias,P. jirovecii Pneumonias,PCP Infections,PCP Pneumonias,Pneumocystis Pneumonias,Pneumocystoses,Pneumonia, P carinii,Pneumonia, P. carinii,Pneumonia, P. jirovecii,Pneumonia, PCP,Pneumonia, Pneumocystis jirovecii,Pneumonias, PCP
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000892 Anti-Infective Agents, Urinary Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. Antiseptics, Urinary,Antiinfective Agents, Urinary,Urinary Anti-Infective Agents,Urinary Antiinfective Agents,Agents, Urinary Anti-Infective,Agents, Urinary Antiinfective,Anti Infective Agents, Urinary,Urinary Anti Infective Agents,Urinary Antiseptics
D013420 Sulfamethoxazole A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208) Sulfamethylisoxazole,Gantanol,Sulfisomezole,Sulphamethoxazole
D014295 Trimethoprim A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported. Proloprim,Trimpex

Related Publications

T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
January 1974, Progress in biochemical pharmacology,
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
October 1976, The Medical journal of Australia,
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
June 1976, The Medical journal of Australia,
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
February 1973, Lancet (London, England),
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
January 1974, Journal of clinical pharmacology,
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
January 1991, Nursing standard (Royal College of Nursing (Great Britain) : 1987),
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
November 1999, Renal failure,
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
December 1972, Lancet (London, England),
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
September 1980, The Journal of infection,
T B Vree, and M Martea, and Y A Hekster, and E F Termond, and R Van Klaveren, and J W Lammers, and J H Berden
January 1995, The Journal of the American Board of Family Practice,
Copied contents to your clipboard!